Shareholder Votes

ZION OIL & GAS INC shareholders approved Approve, in a nonbinding advisory vote, compensation of the Company’s Named Executive Officers at the 2026-06-02 meeting.

“The Company’s common stockholders approved in a nonbinding advisory vote, compensation of the Company’s Named Executive Officers set forth below:”

ZION OIL & GAS INC shareholders approved Ratify the appointment of RBSM, LLP as the Company's auditors for the year ending December 31, 2026 at the 2026-06-02 meeting.

“The Company’s common stockholders ratified the appointment of RBSM, LLP., as the Company's auditors for the year ending December 31, 2026, as follows:”

ZION OIL & GAS INC shareholders approved Election of Class III Directors at the 2026-06-02 meeting.

“The Company’s common stockholders elected each of the Company’s four nominees for Class III Directors to serve a term of three years to expire at the 2029 Annual Meeting of stockholders or until their respective successors are duly elected and qualified, as set forth below:”

COMSTOCK RESOURCES INC shareholders approved Advisory vote on 2025 compensation of named executive officers at the 2026-06-02 meeting.

“Proposal 3. The following votes were cast in the advisory vote on 2025 compensation of our named executive officers: Number of Votes Voted For Number of Votes Voted Against Number of Votes Abstaining Broker Non-Votes Total 264,508,945 526,507 432,344 13,354,680 278,822,476”

COMSTOCK RESOURCES INC shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.

“Proposal 2. The following votes were cast in the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026: Number of Votes Voted For Number of Votes Voted Against Number of Votes Abstaining Total 277,902,269 530,123 390,084 278,822,476”

COMSTOCK RESOURCES INC shareholders approved Election of five nominees to the Board of Directors at the 2026-06-02 meeting.

“Proposal 1. The following votes were cast in the election of the five nominees to the Board of Directors: Name of Nominee Number of Votes Voted For Number of Votes Withheld Broker Non-Votes Total M. Jay Allison 264,394,396 1,073,400 13,354,680 278,822,476 Roland O. Burns 263,030,985 2,436,811 13,354,680 278,822,476 Elizabeth B. Davis 262,713,318 2,754,478 13,354,680 278,822,476 Morris E. Foster 261,753,030 3,714,766 13,354,680 278,822,476 Jim L. Turner 262,745,124 2,722,672 13,354,680 278,822,476”

CRESCENT BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers at the 2026-06-02 meeting.

“Proposal No. 4 - Approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers. 1 YEAR 2 YEARS 3 YEARS Votes ABSTAINED Broker Non-Votes 18,644,881 903 887 521 2,403,515”

CRESCENT BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-02 meeting.

“Proposal No. 3 - Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 18,346,099 300,217 876 2,403,515”

CRESCENT BIOPHARMA, INC. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-02 meeting.

“Proposal No. 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 21,049,101 1,452 154 0”

CRESCENT BIOPHARMA, INC. shareholders approved Election of two Class II directors to serve until the Company's 2029 Annual General Meeting of Shareholders at the 2026-06-02 meeting.

“Proposal No. 1A and Proposal No. 1B - Election of two Class II directors to serve until the Company’s 2029 Annual General Meeting of Shareholders and until their respective successors have been duly elected and qualified or until their earlier death, resignation, disqualification or removal. Votes FOR Votes WITHHELD Broker Non-Votes Jonathan Violin, Ph.D. (Proposal No. 1A) 2,890,000 0 0 Susan Moran, M.D., MSCE (Proposal No. 1B) 21,401,136 136,056 2,403,515”

Valion Bio, Inc. shareholders approved Approval of sale and issuance of common stock pursuant to Common Stock Purchase Agreement with Tumim Stone Capital, LLC (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.

“Votes For Votes Against Abstentions Broker Non-Votes 333,345 153,008”

Valion Bio, Inc. shareholders approved Approval of issuance of shares of common stock upon conversion of Series B Non-Voting Convertible Preferred Stock and exercise of related warrants to 3i, LP (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.

“Votes For Votes Against Abstentions Broker Non-Votes 333,682 152,377 135,011* 637,190”

Valion Bio, Inc. shareholders approved Approval of issuance of shares of common stock upon conversion of Senior Secured Convertible Note and exercise of warrant to 3i, LP (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.

“Votes For Votes Against Abstentions Broker Non-Votes 332,456 153,503 135,111* 637,190”

Valion Bio, Inc. shareholders approved Approval of issuance of shares of common stock upon conversion of Series C Preferred Stock and exercise of related warrants (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.

“Votes For Votes Against Abstentions Broker Non-Votes 332,353 153,606 135,111* 637,190”

Valion Bio, Inc. shareholders approved Ratification of Rosenberg Rich Baker Berman, P.A. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-28 meeting.

“Proposal No. 3: The Company’s stockholders ratified the selection of Rosenberg Rich Baker Berman, P.A.”

Valion Bio, Inc. shareholders approved Approval of Plan Amendment to increase shares authorized under the 2021 Amended and Restated 2021 Equity Incentive Plan by 2,581,608 shares at the 2026-05-28 meeting.

“Votes For Votes Against Abstentions Broker Non-Votes 736,919 134,918 60,707 637,190”

Valion Bio, Inc. shareholders approved Election of one Class II director at the 2026-05-28 meeting.

“Name of Director Votes For Withhold Broker Non-Votes Dean Zikria 873,001 59,543 637,190”

REX AMERICAN RESOURCES Corp shareholders approved Ratification of the appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending January 31, 2027 at the 2026-05-28 meeting.

“5. Ratification of the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending January 31, 2027 : For Against Abstain Broker Non-Votes 29,137,918 116,788 55,543 N/A”

REX AMERICAN RESOURCES Corp shareholders approved Approval of the 2026 Plan at the 2026-05-28 meeting.

“4. Approval of the 2026 Plan : For Against Abstain Broker Non-Votes 27,270,159 421,250 40,594 1,578,247”

REX AMERICAN RESOURCES Corp shareholders approved Adoption of the 2026 Amendment at the 2026-05-28 meeting.

“3. Adoption of the 2026 Amendment : For Against Abstain Broker Non-Votes 28,891,318 384,868 34,063 N/A”

REX AMERICAN RESOURCES Corp shareholders approved Advisory vote on executive compensation at the 2026-05-28 meeting.

“2. Advisory vote on executive compensation : For Against Abstain Broker Non-Votes 26,834,576 854,974 42,452 1,578,248”

REX AMERICAN RESOURCES Corp shareholders approved Election of nine directors at the 2026-05-28 meeting.

“1. Election of nine directors . The shareholders elected each of the nine nominees to the Board of Directors for a one-year term by a majority of votes cast.”

BYLINE BANCORP, INC. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-06-02 meeting.

“Byline’s stockholders ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:”

BYLINE BANCORP, INC. shareholders approved Approval to Amend Shares Offered for Employee Stock Purchase Plan at the 2026-06-02 meeting.

“Byline's stockholders approved an amendment to the Company's Employee Stock Purchase Plan to increase the number of shares of common stock that may be offered under the plan as described in the 2026 Proxy Statement:”

BYLINE BANCORP, INC. shareholders approved Approval to Adopt 2026 Omnibus Incentive Compensation Plan at the 2026-06-02 meeting.

“Byline's stockholders approved the adoption of the Company's 2026 Omnibus Incentive Compensation Plan as described in the 2026 Proxy Statement:”

BYLINE BANCORP, INC. shareholders approved Advisory (non-binding) Vote to Approve Named Executive Officer Compensation at the 2026-06-02 meeting.

“Byline’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers as described in the 2026 Proxy Statement:”

BYLINE BANCORP, INC. shareholders approved Election of Directors at the 2026-06-02 meeting.

“Byline’s stockholders elected ten (10) director nominees to serve a one-year term until the 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified:”

NewAmsterdam Pharma Co N.V. shareholders approved Non-binding advisory vote on 2025 compensation of named executive officers at the 2026-06-02 meeting.

“Proposal 9. The Company’s shareholders approved the 2025 compensation of the Company’s named executive officers by a non-binding, advisory (“Say-on-Pay”) vote. The votes cast were as follows: For Against Abstain Broker Non-Votes 81,100,259 4,946,963 339,780 5,151,610”

NewAmsterdam Pharma Co N.V. shareholders approved Approval of ESPP at the 2026-06-02 meeting.

“Proposal 8. The Company’s shareholders approved the ESPP. The votes cast were as follows: For Against Abstain Broker Non-Votes 86,221,442 139,927 25,633 5,151,610”

NewAmsterdam Pharma Co N.V. shareholders approved Extension of authorization for Board to limit or exclude pre-emption rights for five-year period ending June 2, 2031 at the 2026-06-02 meeting.

“Proposal 7. The Company’s shareholders approved the extension of authorization for the Board of Directors to limit or exclude pre-emption rights, for a five-year period ending June 2, 2031. The votes cast were as follows: For Against Abstain Broker Non-Votes 57,890,766 28,450,917 45,319 5,151,610”

NewAmsterdam Pharma Co N.V. shareholders approved Extension of authorization for Board to issue Ordinary Shares for five-year period ending June 2, 2031 at the 2026-06-02 meeting.

“Proposal 6. The Company’s shareholders approved the extension of authorization for the Board of Directors to issue Ordinary Shares (or rights to subscribe for Ordinary Shares) in the Company’s capital, for a five-year period ending June 2, 2031. The votes cast were as follows: For Against Abstain Broker Non-Votes 59,539,558 26,801,646 45,798 5,151,610”

NewAmsterdam Pharma Co N.V. shareholders approved Re-appointment of two non-executive directors at the 2026-06-02 meeting.

“Proposal 5. The Company’s shareholders approved the re-appointment of each of the two nominees listed below as a non-executive director of the Company, each to serve until the annual general meeting of shareholders in 2030, or until their earlier death, resignation or removal. The votes cast were as follows: Name For Against Abstain Broker Non-Votes John W. Smither 85,375,639 956,620 54,743 5,151,610 Janneke van der Kamp 75,256,863 9,899,189 1,230,950 5,151,610”

NewAmsterdam Pharma Co N.V. shareholders approved Ratification of Deloitte Accountants B.V. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.

“Proposal 4. The Company’s shareholders ratified the selection by the Company’s Audit Committee of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. The votes cast were as follows: For Against Abstain Broker Non-Votes 91,502,639 4,618 31,355 —”

NewAmsterdam Pharma Co N.V. shareholders approved Instruction to Deloitte Accounts B.V. as external auditor for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.

“Proposal 3. The Company’s shareholders approved the instruction to Deloitte Accounts B.V. as the external auditor of the Company’s Dutch statutory annual accounts and Dutch statutory board report (including, to the extent applicable, sustainability reporting) for the fiscal year ending December 31, 2026. The votes cast were as follows: For Against Abstain Broker Non-Votes 91,502,529 4,636 31,447 —”

NewAmsterdam Pharma Co N.V. shareholders approved Discharge from liability for the Company’s directors for fiscal year ended December 31, 2025 at the 2026-06-02 meeting.

“Proposal 2. The Company’s shareholders approved the discharge from liability for the Company’s directors with respect to the performance of their duties during the fiscal year ended December 31, 2025. The votes cast were as follows: For Against Abstain Broker Non-Votes 85,229,605 1,105,840 51,557 5,151,610”

NewAmsterdam Pharma Co N.V. shareholders approved Adoption of Dutch statutory annual accounts for fiscal year ended December 31, 2025 at the 2026-06-02 meeting.

“Proposal 1. The Company’s shareholders approved the adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2025. The votes cast were as follows: For Against Abstain Broker Non-Votes 91,484,326 3,855 50,431 —”

REGENXBIO Inc. shareholders rejected Stock Option Exchange Program for executive employees at the 2026-05-29 meeting.

“Proposal 5 : By the following vote, the stockholders did not approve, a Stock Option Exchange Program for the Company’s executive employees: Votes For Votes Against Votes Abstaining Broker Non-Votes 14,097,815 21,021,531 145,416 7,554,121”

REGENXBIO Inc. shareholders approved Approval of Stock Option Exchange Program for non-executive employees at the 2026-05-29 meeting.

“Proposal 4 : By the following vote, the stockholders approved, the Stock Option Exchange Program for the Company’s non-executive employees: Votes For Votes Against Votes Abstaining Broker Non-Votes 26,352,456 8,853,230 59,076 7,554,121”

REGENXBIO Inc. shareholders approved Advisory vote to approve compensation of named executive officers at the 2026-05-29 meeting.

“Proposal 3 : By the following vote, the stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement: Votes For Votes Against Votes Abstaining Broker Non-Votes 32,392,302 2,722,825 149,635 7,554,121”

REGENXBIO Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for year ending December 31, 2026 at the 2026-05-29 meeting.

“Proposal 2 : By the following vote, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026: Votes For Votes Against Votes Abstaining Broker Non-Votes 42,526,553 244,785 47,545 0”

REGENXBIO Inc. shareholders approved Election of three Class II directors at the 2026-05-29 meeting.

“Proposal 1 : By the following vote, the following three persons were elected to serve as Class II directors until the Company’s 2029 annual meeting of stockholders: Nominee Votes For Votes Withheld Broker Non-Votes Jean Bennett, M.D., Ph.D. 24,025,836 11,238,926 7,554,121 A.N. “Jerry” Karabelas, Ph.D. 27,124,923 8,139,839 7,554,121 Daniel Tassé 32,039,753 3,225,009 7,554,121”

Keenova Therapeutics plc shareholders approved Approve an amendment to the Company's articles of association (Special Resolution) at the 2026-06-02 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES 25,476,547 6,345 0 310,829”

Keenova Therapeutics plc shareholders approved Approve the reduction of Company capital (Special Resolution) at the 2026-06-02 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES 25,256,218 35,379 191,295 310,829”

Keenova Therapeutics plc shareholders approved Advisory non-binding vote to approve the frequency of future advisory non-binding votes to approve the Company's executive compensation at the 2026-06-02 meeting.

“1 YEAR 2 YEARS 3 YEARS ABSTAIN BROKER NON-VOTES 25,117,919 172,952 726 191,295 310,829”

Keenova Therapeutics plc shareholders approved Advisory non-binding vote to approve the Company's executive compensation at the 2026-06-02 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES 24,965,301 326,296 191,295 310,829”

Keenova Therapeutics plc shareholders approved Advisory non-binding vote to approve the re-appointment of PricewaterhouseCoopers LLP as independent auditors and to authorize the Audit Committee to set the auditors’ remuneration at the 2026-06-02 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES 25,602,426 0 191,295 0”

Keenova Therapeutics plc shareholders approved Election of directors to hold office until the 2027 Annual General Meeting at the 2026-06-02 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES Paul M. Bisaro 25,282,713 8,884 191,295 310,829”

Viridian Therapeutics, Inc.\DE shareholders approved Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company’s named executive officers at the 2026-06-02 meeting.

“4. Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company’s named executive officers: 1 Year 2 Years 3 Years Abstain 86,084,347 29,762 517,682 207,355”

Viridian Therapeutics, Inc.\DE shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-02 meeting.

“3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers: For Against Abstentions Broker Non-Votes 83,512,086 3,113,724 213,336 6,733,104”

Viridian Therapeutics, Inc.\DE shareholders approved Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-02 meeting.

“2. Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstentions Broker Non-Votes 92,866,008 512,582 193,660 —”